ELIZABETH DIERKSEN EUSCHER
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endometrial Neoplasms | 19 | 2023 | 1341 | 2.970 |
Why?
|
| Carcinoma, Endometrioid | 8 | 2023 | 323 | 2.000 |
Why?
|
| Sentinel Lymph Node | 6 | 2020 | 216 | 1.720 |
Why?
|
| Uterine Neoplasms | 9 | 2022 | 545 | 1.340 |
Why?
|
| Ovarian Neoplasms | 16 | 2023 | 4638 | 1.300 |
Why?
|
| Carcinoma | 5 | 2023 | 2578 | 1.120 |
Why?
|
| Cystadenocarcinoma, Serous | 7 | 2021 | 486 | 1.070 |
Why?
|
| Peritoneal Neoplasms | 8 | 2022 | 821 | 1.010 |
Why?
|
| Carcinosarcoma | 4 | 2018 | 146 | 0.940 |
Why?
|
| Sentinel Lymph Node Biopsy | 6 | 2020 | 1415 | 0.920 |
Why?
|
| Mesonephroma | 1 | 2023 | 17 | 0.920 |
Why?
|
| Hysterectomy | 6 | 2020 | 611 | 0.800 |
Why?
|
| Endodermal Sinus Tumor | 2 | 2019 | 47 | 0.750 |
Why?
|
| Wolffian Ducts | 1 | 2020 | 24 | 0.740 |
Why?
|
| Uterine Cervical Neoplasms | 10 | 2023 | 1833 | 0.720 |
Why?
|
| Immunohistochemistry | 16 | 2022 | 7548 | 0.670 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 2 | 2019 | 328 | 0.670 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 2 | 2017 | 108 | 0.660 |
Why?
|
| Lymphatic Metastasis | 12 | 2020 | 4844 | 0.600 |
Why?
|
| Fallopian Tube Neoplasms | 3 | 2021 | 153 | 0.570 |
Why?
|
| Salpingectomy | 1 | 2016 | 43 | 0.550 |
Why?
|
| Urogenital Neoplasms | 1 | 2017 | 108 | 0.550 |
Why?
|
| Vulvar Neoplasms | 2 | 2021 | 236 | 0.520 |
Why?
|
| Lymph Nodes | 6 | 2020 | 2967 | 0.510 |
Why?
|
| Adenocarcinoma, Clear Cell | 2 | 2017 | 178 | 0.510 |
Why?
|
| Ovariectomy | 1 | 2016 | 330 | 0.510 |
Why?
|
| Lymph Node Excision | 6 | 2019 | 1959 | 0.510 |
Why?
|
| Adenocarcinoma | 11 | 2023 | 7789 | 0.490 |
Why?
|
| Myometrium | 1 | 2013 | 79 | 0.460 |
Why?
|
| Endometriosis | 4 | 2023 | 214 | 0.460 |
Why?
|
| Genital Neoplasms, Female | 1 | 2020 | 735 | 0.450 |
Why?
|
| Biomarkers, Tumor | 15 | 2022 | 10331 | 0.440 |
Why?
|
| Xanthomatosis | 1 | 2012 | 21 | 0.420 |
Why?
|
| Carcinoma, Verrucous | 1 | 2012 | 14 | 0.410 |
Why?
|
| Neoplasm Grading | 6 | 2021 | 1742 | 0.410 |
Why?
|
| Neoplasm Staging | 15 | 2020 | 13658 | 0.410 |
Why?
|
| Carcinoma, Squamous Cell | 5 | 2020 | 5437 | 0.400 |
Why?
|
| Female | 51 | 2023 | 141928 | 0.400 |
Why?
|
| Aged, 80 and over | 21 | 2021 | 29902 | 0.340 |
Why?
|
| Teratoma | 3 | 2019 | 236 | 0.330 |
Why?
|
| Aged | 30 | 2023 | 70117 | 0.320 |
Why?
|
| Neuroectodermal Tumors, Primitive, Peripheral | 1 | 2008 | 36 | 0.310 |
Why?
|
| Middle Aged | 33 | 2023 | 86204 | 0.310 |
Why?
|
| Adult | 31 | 2023 | 77950 | 0.310 |
Why?
|
| Neoplasm Invasiveness | 6 | 2020 | 3981 | 0.310 |
Why?
|
| Humans | 51 | 2023 | 261506 | 0.280 |
Why?
|
| WT1 Proteins | 1 | 2005 | 106 | 0.250 |
Why?
|
| Polyps | 1 | 2005 | 74 | 0.250 |
Why?
|
| Lymphatic Diseases | 1 | 2004 | 128 | 0.240 |
Why?
|
| Asbestos | 1 | 2022 | 35 | 0.210 |
Why?
|
| Carcinoma, Neuroendocrine | 2 | 2021 | 716 | 0.210 |
Why?
|
| Carcinoid Tumor | 2 | 2019 | 280 | 0.210 |
Why?
|
| Neoplasms, Connective Tissue | 1 | 2022 | 20 | 0.210 |
Why?
|
| Epithelioid Cells | 1 | 2022 | 43 | 0.200 |
Why?
|
| Neoadjuvant Therapy | 4 | 2021 | 4975 | 0.200 |
Why?
|
| Predictive Value of Tests | 8 | 2022 | 4892 | 0.200 |
Why?
|
| Endometrium | 3 | 2020 | 470 | 0.200 |
Why?
|
| Carcinoma, Large Cell | 1 | 2021 | 94 | 0.190 |
Why?
|
| Diagnosis, Differential | 6 | 2022 | 4744 | 0.190 |
Why?
|
| Myofibroblasts | 1 | 2022 | 133 | 0.190 |
Why?
|
| Pelvis | 3 | 2017 | 362 | 0.190 |
Why?
|
| Vaginal Neoplasms | 2 | 2014 | 152 | 0.180 |
Why?
|
| Biopsy | 6 | 2022 | 3443 | 0.180 |
Why?
|
| PAX8 Transcription Factor | 2 | 2016 | 55 | 0.180 |
Why?
|
| Young Adult | 9 | 2022 | 21445 | 0.180 |
Why?
|
| Dysgerminoma | 1 | 2019 | 42 | 0.180 |
Why?
|
| Chemotherapy, Adjuvant | 5 | 2021 | 3890 | 0.170 |
Why?
|
| Endometrial Hyperplasia | 1 | 2020 | 112 | 0.170 |
Why?
|
| Carcinoma, Adenosquamous | 2 | 2017 | 103 | 0.170 |
Why?
|
| Chemoradiotherapy, Adjuvant | 3 | 2018 | 565 | 0.170 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2022 | 10035 | 0.160 |
Why?
|
| Carcinoma, Small Cell | 1 | 2021 | 408 | 0.160 |
Why?
|
| Pathologists | 1 | 2019 | 91 | 0.160 |
Why?
|
| Disease-Free Survival | 2 | 2023 | 10001 | 0.160 |
Why?
|
| Risk Factors | 5 | 2020 | 17523 | 0.150 |
Why?
|
| Mesothelioma | 1 | 2022 | 544 | 0.150 |
Why?
|
| Disease Progression | 2 | 2020 | 6682 | 0.150 |
Why?
|
| Neoplasms, Second Primary | 1 | 2005 | 1350 | 0.140 |
Why?
|
| Time Factors | 4 | 2020 | 12926 | 0.140 |
Why?
|
| Gynecology | 1 | 2019 | 217 | 0.140 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2020 | 469 | 0.140 |
Why?
|
| Nuclear Proteins | 2 | 2023 | 3343 | 0.140 |
Why?
|
| Societies, Medical | 2 | 2019 | 1335 | 0.130 |
Why?
|
| Repressor Proteins | 1 | 2023 | 1664 | 0.130 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 2008 | 551 | 0.120 |
Why?
|
| Sarcoma, Endometrial Stromal | 1 | 2013 | 14 | 0.120 |
Why?
|
| Republic of Korea | 1 | 2013 | 70 | 0.120 |
Why?
|
| Ontario | 1 | 2013 | 98 | 0.120 |
Why?
|
| Treatment Outcome | 10 | 2022 | 32848 | 0.120 |
Why?
|
| Mexico | 1 | 2013 | 259 | 0.110 |
Why?
|
| Conization | 1 | 2012 | 36 | 0.110 |
Why?
|
| Frozen Sections | 1 | 2012 | 105 | 0.100 |
Why?
|
| Positron-Emission Tomography | 2 | 2011 | 2173 | 0.100 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2015 | 436 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 2 | 2019 | 2403 | 0.100 |
Why?
|
| Sciatica | 1 | 2010 | 7 | 0.100 |
Why?
|
| Receptor, ErbB-2 | 1 | 2021 | 2518 | 0.100 |
Why?
|
| Intraoperative Care | 1 | 2012 | 259 | 0.100 |
Why?
|
| Menstrual Cycle | 1 | 2010 | 56 | 0.100 |
Why?
|
| Cervix Uteri | 1 | 2012 | 253 | 0.090 |
Why?
|
| Laparoscopy | 3 | 2020 | 1225 | 0.090 |
Why?
|
| Aorta, Abdominal | 1 | 2011 | 152 | 0.090 |
Why?
|
| Adolescent | 5 | 2022 | 31252 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2018 | 6207 | 0.090 |
Why?
|
| Remission Induction | 1 | 2016 | 3569 | 0.090 |
Why?
|
| Aorta | 2 | 2010 | 692 | 0.090 |
Why?
|
| Colorectal Neoplasms | 2 | 2020 | 3578 | 0.090 |
Why?
|
| Salpingo-oophorectomy | 2 | 2020 | 50 | 0.090 |
Why?
|
| Kidney Neoplasms | 1 | 2023 | 3022 | 0.080 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2021 | 3552 | 0.080 |
Why?
|
| Retrospective Studies | 10 | 2022 | 37905 | 0.080 |
Why?
|
| Calmodulin-Binding Proteins | 1 | 2008 | 86 | 0.080 |
Why?
|
| RNA-Binding Protein EWS | 1 | 2008 | 98 | 0.080 |
Why?
|
| Texas | 2 | 2016 | 6311 | 0.070 |
Why?
|
| Age Factors | 1 | 2016 | 5377 | 0.070 |
Why?
|
| Coloring Agents | 2 | 2017 | 234 | 0.070 |
Why?
|
| Indocyanine Green | 2 | 2017 | 117 | 0.070 |
Why?
|
| Logistic Models | 1 | 2013 | 3441 | 0.070 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 4298 | 0.070 |
Why?
|
| Incidence | 1 | 2016 | 5673 | 0.070 |
Why?
|
| CA-125 Antigen | 1 | 2007 | 226 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2011 | 7551 | 0.060 |
Why?
|
| Glioma | 1 | 2015 | 1963 | 0.060 |
Why?
|
| Melanoma | 2 | 2020 | 5317 | 0.060 |
Why?
|
| Gene Rearrangement | 1 | 2008 | 783 | 0.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 15862 | 0.060 |
Why?
|
| Technetium Tc 99m Sulfur Colloid | 2 | 2017 | 115 | 0.060 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2008 | 519 | 0.060 |
Why?
|
| SOXF Transcription Factors | 1 | 2023 | 34 | 0.060 |
Why?
|
| Prognosis | 3 | 2019 | 21713 | 0.050 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2022 | 178 | 0.050 |
Why?
|
| RNA-Binding Proteins | 1 | 2008 | 984 | 0.050 |
Why?
|
| Merkel cell polyomavirus | 1 | 2021 | 30 | 0.050 |
Why?
|
| Peritoneum | 1 | 2022 | 150 | 0.050 |
Why?
|
| Prophylactic Surgical Procedures | 1 | 2020 | 23 | 0.050 |
Why?
|
| Homozygote | 1 | 2022 | 717 | 0.050 |
Why?
|
| Mutation | 1 | 2020 | 15179 | 0.050 |
Why?
|
| Fallopian Tubes | 1 | 2020 | 119 | 0.040 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2021 | 155 | 0.040 |
Why?
|
| Observer Variation | 1 | 2021 | 671 | 0.040 |
Why?
|
| Sequence Deletion | 1 | 2022 | 875 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2022 | 9244 | 0.040 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2022 | 475 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2020 | 11538 | 0.040 |
Why?
|
| Transcription Factors | 2 | 2008 | 5270 | 0.040 |
Why?
|
| Survival Analysis | 2 | 2020 | 9180 | 0.040 |
Why?
|
| Germ-Line Mutation | 1 | 2022 | 1046 | 0.040 |
Why?
|
| Ovary | 1 | 2020 | 668 | 0.030 |
Why?
|
| United States | 1 | 2013 | 15433 | 0.030 |
Why?
|
| Paired Box Transcription Factors | 1 | 2016 | 134 | 0.030 |
Why?
|
| Risk | 1 | 2020 | 1972 | 0.030 |
Why?
|
| Alleles | 1 | 2021 | 2437 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2008 | 4821 | 0.030 |
Why?
|
| DNA Mismatch Repair | 1 | 2016 | 268 | 0.030 |
Why?
|
| Factor Analysis, Statistical | 1 | 2015 | 356 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2017 | 4971 | 0.030 |
Why?
|
| Prospective Studies | 3 | 2017 | 12873 | 0.030 |
Why?
|
| Microsatellite Instability | 1 | 2016 | 400 | 0.030 |
Why?
|
| Antibodies | 1 | 2016 | 838 | 0.030 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2016 | 356 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2018 | 2231 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 14889 | 0.030 |
Why?
|
| Hospitals, Community | 1 | 2012 | 79 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 2291 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2021 | 16273 | 0.030 |
Why?
|
| Hospitals, University | 1 | 2012 | 209 | 0.030 |
Why?
|
| Vagina | 1 | 2014 | 317 | 0.030 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2017 | 833 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2017 | 1301 | 0.020 |
Why?
|
| Liver Neoplasms | 1 | 2007 | 4557 | 0.020 |
Why?
|
| Sciatic Nerve | 1 | 2010 | 112 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 6009 | 0.020 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2012 | 219 | 0.020 |
Why?
|
| Robotic Surgical Procedures | 1 | 2017 | 481 | 0.020 |
Why?
|
| Electromyography | 1 | 2010 | 226 | 0.020 |
Why?
|
| Decompression, Surgical | 1 | 2010 | 143 | 0.020 |
Why?
|
| Cell Differentiation | 2 | 2013 | 4078 | 0.020 |
Why?
|
| Muscular Atrophy | 1 | 2010 | 105 | 0.020 |
Why?
|
| Northern Ireland | 1 | 2007 | 4 | 0.020 |
Why?
|
| Thyroid Nuclear Factor 1 | 1 | 2007 | 52 | 0.020 |
Why?
|
| Carboplatin | 1 | 2011 | 823 | 0.020 |
Why?
|
| Antineoplastic Agents | 2 | 2021 | 14289 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2013 | 1987 | 0.020 |
Why?
|
| Child | 2 | 2021 | 29154 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2015 | 4988 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2008 | 660 | 0.020 |
Why?
|
| Pelvic Neoplasms | 1 | 2007 | 189 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2008 | 760 | 0.020 |
Why?
|
| Abdominal Neoplasms | 1 | 2007 | 231 | 0.020 |
Why?
|
| Age of Onset | 1 | 2007 | 827 | 0.020 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2010 | 1226 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2011 | 1996 | 0.010 |
Why?
|
| Phenotype | 1 | 2015 | 6295 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2007 | 1620 | 0.010 |
Why?
|
| Gene Expression | 1 | 2008 | 3570 | 0.010 |
Why?
|
| Survival Rate | 1 | 2011 | 12221 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2010 | 7702 | 0.010 |
Why?
|
| Male | 1 | 2021 | 123000 | 0.010 |
Why?
|
| Animals | 1 | 2013 | 59536 | 0.010 |
Why?
|